Wasatch Advisors Lowered Its Allegiant Travel Co. (ALGT) Stake; 4 Analysts Are Bullish Immune Pharmaceuticals Inc. (IMNP) Last Week

March 14, 2018 - By Richard Conner

Among 4 analysts covering Immune Pharma (NASDAQ:IMNP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immune Pharma had 4 analyst reports since October 8, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, October 8 by TH Capital. On Tuesday, October 13 the stock rating was maintained by Chardan Capital Markets with “Buy”. The company was initiated on Thursday, October 8 by Roth Capital. See Immune Pharmaceuticals Inc. (NASDAQ:IMNP) latest ratings:

05/01/2018 Broker: Maxim Group Rating: Buy New Target: $3.0

Wasatch Advisors Inc decreased Allegiant Travel Co. (ALGT) stake by 4.09% reported in 2017Q3 SEC filing. Wasatch Advisors Inc sold 29,374 shares as Allegiant Travel Co. (ALGT)’s stock declined 16.77%. The Wasatch Advisors Inc holds 689,118 shares with $90.76M value, down from 718,492 last quarter. Allegiant Travel Co. now has $2.81 billion valuation. The stock decreased 1.61% or $2.9 during the last trading session, reaching $176.7. About 29,249 shares traded. Allegiant Travel Company (NASDAQ:ALGT) has risen 1.38% since March 14, 2017 and is uptrending. It has underperformed by 15.32% the S&P500.

Since October 27, 2017, it had 0 insider purchases, and 3 sales for $33.33 million activity. 5,872 Allegiant Travel Company (NASDAQ:ALGT) shares with value of $808,188 were sold by Sheldon Scott. Shares for $2.07M were sold by GALLAGHER MAURICE J JR.

Investors sentiment increased to 0.89 in Q3 2017. Its up 0.09, from 0.8 in 2017Q2. It improved, as 28 investors sold ALGT shares while 61 reduced holdings. 22 funds opened positions while 49 raised stakes. 13.79 million shares or 4.93% more from 13.14 million shares in 2017Q2 were reported. 1,095 are held by Oppenheimer Asset Mgmt. Inv Of America Incorporated owns 1.52% invested in Allegiant Travel Company (NASDAQ:ALGT) for 68,484 shares. Wasatch Advsr Inc reported 689,118 shares. 12,018 are owned by Invesco Limited. Research Glob Invsts, California-based fund reported 399,089 shares. 599,399 were reported by Neuberger Berman Ltd. Parametrica Mngmt Ltd holds 3,459 shares or 0.19% of its portfolio. Alps Advisors Inc holds 0% or 3,966 shares in its portfolio. Rhumbline Advisers stated it has 27,468 shares. Louisiana State Employees Retirement System owns 5,100 shares or 0.03% of their US portfolio. Commercial Bank Of Montreal Can accumulated 7,365 shares. Point72 Asia (Hong Kong) Ltd accumulated 0% or 39 shares. 11,392 were reported by State Of Tennessee Treasury Department. Wesbanco Commercial Bank Incorporated accumulated 15,000 shares or 0.1% of the stock. Daiwa Group Inc accumulated 1,500 shares or 0% of the stock.

Wasatch Advisors Inc increased Inovio Pharmaceuticals Inc. (NASDAQ:INO) stake by 80,513 shares to 2.69M valued at $17.06M in 2017Q3. It also upped Proofpoint Inc. (NASDAQ:PFPT) stake by 61,732 shares and now owns 790,258 shares. Tucows Inc. (NASDAQ:TCX) was raised too.

Analysts await Allegiant Travel Company (NASDAQ:ALGT) to report earnings on April, 24. They expect $3.02 earnings per share, up 20.80% or $0.52 from last year’s $2.5 per share. ALGT’s profit will be $48.03M for 14.63 P/E if the $3.02 EPS becomes a reality. After $2.71 actual earnings per share reported by Allegiant Travel Company for the previous quarter, Wall Street now forecasts 11.44% EPS growth.

Among 14 analysts covering Allegiant Travel (NASDAQ:ALGT), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Allegiant Travel had 53 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Mkt Perform” rating by Raymond James given on Monday, November 30. The stock of Allegiant Travel Company (NASDAQ:ALGT) earned “Hold” rating by Stifel Nicolaus on Wednesday, January 10. Citigroup maintained Allegiant Travel Company (NASDAQ:ALGT) rating on Tuesday, September 26. Citigroup has “Buy” rating and $168 target. On Thursday, August 17 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The rating was maintained by Imperial Capital with “Outperform” on Tuesday, November 22. Stifel Nicolaus maintained it with “Buy” rating and $210.0 target in Wednesday, January 31 report. As per Monday, February 5, the company rating was maintained by Morgan Stanley. As per Tuesday, April 12, the company rating was maintained by Credit Suisse. The rating was upgraded by Bank of America to “Buy” on Tuesday, January 9. Cowen & Co maintained it with “Market Perform” rating and $152 target in Wednesday, November 30 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.